— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.
— Product revenues grew by 30% to $39.3 million versus $38.97 million expected. The top line was driven by an increase in the US net product revenue.
— The supply of free drugs distributed to eligible patients in the U.S. through the Rubraca patient assistance program for Q4 2019 was 18% of the overall US commercial supply, compared to 26% reported in Q4 2018.
— Research and development expenses increased by 2% year-over-year due primarily to higher research and development costs for rucaparib clinical trials.
— The company believes it has sufficient cash, cash equivalents, and available-for-sale securities to fund its operating plan into the second half of 2021. This is based on anticipated revenue, spending, available financing sources, and existing cash.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to
